Wyeth and Teva extend pantoprazole standstill period
22 January 2008 00:00 in Pharmaceutical Company Product News
Wyeth Pharmaceuticals, a division of Wyeth, has this week announced an agreement with Teva Pharmaceuticals for the extention of the standstill period relating to Teva's launch of generic pantoprazole.
The period, previously announced on December 24th 2007, has been extended for a further ten days as the companies continue to discover whether or not a settlement in their patent litigation can be reached.
Wyeth announced that this new extension will now expire on January 31st 2008.
This announcement follows the launch by Teva on December 21st 2007 of a generic form of Wyeth's Protonix (pantoprazole), with both firms agreeing to a month-long standstill period.
"During this period, Teva agreed not to sell or ship additional generic pantoprazole product in order to allow the parties an opportunity to explore whether settlement was possible," Wyeth reports.
The standstill period would automatically end if Wyeth starts the sale of a generic version of Protonix itself.
Wyeth adds that while the discussions of both parties are continuing, this fact does not guarantee the reaching of a settlement, as the complexity of the situation has resulted in a number of large obstacles to a potential settlement.
The firm announced a motion for a preliminary injunction against Teva and Sun Pharmaceuticals regarding the possible launch of a generic formulation of Protonix in August 2007.
Other news stories from 22/01/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency